Table 3.

Combined effects of NSAID use and genotype on colorectal cancer risk

Aspirin/NSAID useEveryone
NeverCurrent/ever
VDR
    LL or bb (n)473/395303/414
    LS or Bb498/471368/498
    SS or BB171/206130/181
    LL or bb [OR (95% CI)]1.000.59 (0.48–0.72)
    LS or Bb0.91 (0.75–1.09)0.61 (0.50–0.74)
    SS or BB0.70 (0.54–0.89)0.59 (0.45–0.77)
    P interactiona0.01
IRS1
    GR/RR (n)171/116111/134
    GG971/943693/952
    GR/RR [OR (95% CI)]1.000.52 (0.37–0.74)
    GG0.67 (0.52–0.87)0.46 (0.35–0.60)
    P interaction0.02
IRS2
    GG (n)456/445332/453
    GD431/475314/497
    DD130/13793/134
    GG [OR (95% CI)]1.000.70 (0.58–0.85)
    GD0.91 (0.75–1.09)0.60 (0.50–0.74)
    DD0.93 (0.71–1.23)0.65 (0.48–0.88)
    P interaction0.93
IGF1
    192/192 (n)439/434314/441
    192/no 192536/470370/508
    no 192159/157113/117
    192/192 [OR (95% CI)]1.000.68 (0.56–0.83)
    192/no 1921.15 (0.96–1.39)0.71 (0.58–0.86)
    no 1920.98 (0.76–1.28)0.78 (0.58–1.03)
    P interaction0.35
IGFBP3
    CC (n)315/295204/309
    CA572/541417/537
    AA250/221174/240
    CC [OR (95% CI)]1.000.60 (0.47–0.77)
    CA0.97 (0.79–1.19)0.68 (0.56–0.84)
    AA1.04 (0.82–1.33)0.64 (0.50–0.83)
    P interaction0.54
  • Note: ORs and 95% CIs are adjusted for age, BMI, energy intake, long-term vigorous physical activity, calcium, dietary fiber, and usual number of cigarettes smoked.

  • a Interactions based on RERI.